-$0.21 Earnings Per Share Expected for Genprex Inc (NASDAQ:GNPX) This Quarter

Analysts expect Genprex Inc (NASDAQ:GNPX) to announce earnings per share (EPS) of ($0.21) for the current quarter, Zacks reports. Zero analysts have issued estimates for Genprex’s earnings. Genprex reported earnings of ($0.45) per share during the same quarter last year, which suggests a positive year over year growth rate of 53.3%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, August 13th.

On average, analysts expect that Genprex will report full-year earnings of ($0.87) per share for the current financial year. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Genprex.

Genprex (NASDAQ:GNPX) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.09.

Several research firms have commented on GNPX. Maxim Group reissued a “hold” rating on shares of Cytori Therapeutics in a research report on Monday, April 1st. Noble Financial assumed coverage on Genprex in a research report on Monday, April 29th. They issued an “outperform” rating and a $5.00 price objective on the stock. Finally, Zacks Investment Research upgraded HAYS PLC/ADR from a “sell” rating to a “hold” rating in a research note on Tuesday, June 18th.

NASDAQ:GNPX traded up $0.01 during mid-day trading on Friday, hitting $1.07. The company had a trading volume of 100 shares, compared to its average volume of 32,331. The business has a fifty day simple moving average of $1.38. Genprex has a 1 year low of $0.95 and a 1 year high of $7.95. The company has a market capitalization of $17.32 million, a price-to-earnings ratio of -1.18 and a beta of 1.49.

Genprex Company Profile

Genprex, Inc operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells.

Featured Story: Understanding Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on Genprex (GNPX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit